ARMYDA-3 (AF ancillary study) 2006

1 Treatments

Studied treatment  atorvastatin 40mg daily

Control treatment  placebo

Concomittant treatments  -

Age (yr)  66 y

2 Patients

Patients  patients with scheduled cardiac surgery without history of AF

Inclusion criteria  -

Exclusion criteria  -

Hypertension (%)  87%

Diabetes (%)  37%

CAD (%)  84%

LVEF (%)  52%

beta-blocker use (%)  66%

ACEI (%)  49%

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes  101/99

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF</td>
<td>35/101</td>
<td>56/99</td>
<td>0.61 [0.35; 1.08]</td>
</tr>
</tbody>
</table>
5 References